Innovation Showcase Friday lunchtime
Pluripotent Stem cells research has generated tremendous excitement, and holds promise for the treatment of many uncured diseases. Early stage clinical trials using differentiated induced pluripotent stem cells (iPS) show great potential in cell-based therapeutics. Bridging the gap between research models and clinical applications is the utmost goal to ensure clinically relevant stem cell products. The first part of this innovation showcase will present a research work on SNF5 , which is one of the core subunits of the SWI/SNF chromatin-remodeling complex. Mutations in this protein might have significant effects on the epigenetic state of human embryonic stem cells and on their phenotype and precise levels of SNF5 are required in order to preserve the pluripotent state of the cells. The second part will focus on the manufacturing of clinical grade human iPS under cGMP conditions as a critical part of the translation from research to clinical therapeutics. The innovation showcase will address the challenges of the generation, expansion and storage of iPS cells, including tissue biopsies, xeno-free culture procedures and raw materials, testing and cryopreservation.
Innovation Showcase: Biological Industries
11:30 - 12:30
11:30 - 12:30
Innovation Showcase: THE PROMISE OF INDUCED PLURIPOTENT STEM CELLS: BASIC RESEARCH AND CLINICAL GRADE MANUFACTURING - Biological Industries